Comment from JENNIFER RYKERT-DEAN
AnonymousOpposeAdvocacy
Summary: The National Right to Life Committee (NRLC) opposes the proposed action to remove REMS for mifepristone. They argue that the drug poses risks to women's safety and call for the FDA to instead restore in-person dispensing, reinstate full adverse event reporting, and eventually reverse the drug's approval.
I agree with the position of the National Right to Life Committee. NRLC strongly urges the FDA to reject Citizen Petition FDA-2025-P1576-0001. Removing REMS for mifepristone ignores established medical risks, compromises women’s safety, and politicizes a regulatory process that should be rooted in evidence and public health—not the abortion industry's profit and political agenda. We urge the agency, at a minimum, to restore in-person dispensing, reinstate full adverse event reporting, and initiate independent post-market surveillance studies to assess the true impact of mifepristone use. However, because the drug is most often used on the healthy mothers of healthy babies and, by its very nature, is designed to kill, it can also put the mother’s life in jeopardy. We call upon the FDA to reverse its approval of the mifepristone/misoprostol protocol ensuring that American women are protected from a drug that kills unborn children and endangers women’s lives.